Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 05, 2015 08:00 ET | Source: EPIRUS Biopharmaceuticals, Inc.

EPIRUS Biopharmaceuticals Joins Biosimilars Forum to Help Educate Patients and Healthcare Providers on Importance of Biosimilars

BOSTON, Nov. 05, 2015 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal...
October 29, 2015 07:00 ET | Source: EPIRUS Biopharmaceuticals, Inc.

EPIRUS Biopharmaceuticals to Release Third Quarter 2015 Financial Results and Provide Business Update

BOSTON, Oct. 29, 2015 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal...
September 09, 2015 06:00 ET | Source: EPIRUS Biopharmaceuticals, Inc.

EPIRUS Biopharmaceuticals Expands Biosimilar Pipeline and Capabilities Through Acquisition of Bioceros

Combined companies’ product pipeline targets reference biologics with sales of $29 billion in 2014Pipeline expanded to include biosimilars to Soliris®, STELARA® and SIMPONI® Capabilities...
August 07, 2015 07:00 ET | Source: EPIRUS Biopharmaceuticals, Inc.

EPIRUS Biopharmaceuticals Reports Second Quarter 2015 Financial Results

BOSTON, Aug. 07, 2015 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a Boston-based, pure-play biosimilar company focused on the global development and commercialization of...
August 04, 2015 07:00 ET | Source: EPIRUS Biopharmaceuticals, Inc.

EPIRUS Biopharmaceuticals to Present at Wedbush PacGrow Healthcare Conference

BOSTON, Aug. 04, 2015 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a Boston-based, pure-play biosimilar company focused on the global development and commercialization of...
July 14, 2015 06:00 ET | Source: EPIRUS Biopharmaceuticals, Inc.

EPIRUS Biopharmaceuticals and Polpharma Group Enter Into a Multi-Product, Multi-Region, Profit-Sharing Collaboration to Advance Biosimilar Portfolio Targeting $6 Billion Addressable Innovator Market

Profit-sharing collaboration focused on the commercialization of EPIRUS’ biosimilars pipeline in EU, Middle East, Turkey, Russia and CIS territories ("Territories")EPIRUS retains commercial rights to...
June 10, 2015 07:00 ET | Source: EPIRUS Biopharmaceuticals, Inc.

EPIRUS Biopharmaceuticals Presents New BOW015 (Infliximab Biosimilar) Data at the European League Against Rheumatism Annual Congress (EULAR 2015)

BOSTON, June 10, 2015 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a Boston-based biopharmaceutical company focused on the global development and commercialization of...
May 14, 2015 07:00 ET | Source: EPIRUS Biopharmaceuticals, Inc.

EPIRUS Biopharmaceuticals and mAbxience Sign Latin America Distribution Deal for Infliximab Biosimilar, BOW015

BOSTON, May 14, 2015 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS) and mAbxience, a biopharmaceutical company specialized in research, development and manufacturing of biosimilars,...
May 12, 2015 07:00 ET | Source: EPIRUS Biopharmaceuticals, Inc.

EPIRUS Biopharmaceuticals Reports First Quarter 2015 Financial Results

BOSTON, May 12, 2015 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar...
May 07, 2015 07:00 ET | Source: EPIRUS Biopharmaceuticals, Inc.

EPIRUS Biopharmaceuticals to Present at Bank of America Merrill Lynch 2015 Healthcare Conference

BOSTON, May 7, 2015 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar...